KR102644045B1 - 신규한 소분자 화합물 - Google Patents

신규한 소분자 화합물 Download PDF

Info

Publication number
KR102644045B1
KR102644045B1 KR1020207010525A KR20207010525A KR102644045B1 KR 102644045 B1 KR102644045 B1 KR 102644045B1 KR 1020207010525 A KR1020207010525 A KR 1020207010525A KR 20207010525 A KR20207010525 A KR 20207010525A KR 102644045 B1 KR102644045 B1 KR 102644045B1
Authority
KR
South Korea
Prior art keywords
disease
cancer
cpt
pharmaceutical composition
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207010525A
Other languages
English (en)
Korean (ko)
Other versions
KR20200053560A (ko
Inventor
빙웨이 루
Original Assignee
셀리퓨트, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀리퓨트, 인코포레이티드 filed Critical 셀리퓨트, 인코포레이티드
Publication of KR20200053560A publication Critical patent/KR20200053560A/ko
Application granted granted Critical
Publication of KR102644045B1 publication Critical patent/KR102644045B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020207010525A 2017-09-13 2018-09-12 신규한 소분자 화합물 Active KR102644045B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558323P 2017-09-13 2017-09-13
US62/558,323 2017-09-13
PCT/US2018/050689 WO2019055528A1 (en) 2017-09-13 2018-09-12 NEW COMPOUND WITH SMALL MOLECULES

Publications (2)

Publication Number Publication Date
KR20200053560A KR20200053560A (ko) 2020-05-18
KR102644045B1 true KR102644045B1 (ko) 2024-03-05

Family

ID=65723058

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207010525A Active KR102644045B1 (ko) 2017-09-13 2018-09-12 신규한 소분자 화합물

Country Status (9)

Country Link
US (3) US11186550B2 (https=)
EP (1) EP3681874B1 (https=)
JP (1) JP7170341B2 (https=)
KR (1) KR102644045B1 (https=)
CN (1) CN111372921B (https=)
AU (1) AU2018331371C1 (https=)
CA (1) CA3075649A1 (https=)
IL (1) IL273242B2 (https=)
WO (1) WO2019055528A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3075649A1 (en) 2017-09-13 2019-03-21 Cerepeut, Inc. A novel small molecule compound
CA3131294A1 (en) * 2019-02-27 2020-09-03 Cerepeut, Inc. Quinazolinone compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150164896A1 (en) 2013-12-13 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368434B2 (en) 2002-06-27 2008-05-06 The Endowment For Research In Human Biology, Inc. Compounds useful for the inhibition of ALDH
WO2005051974A2 (en) 2003-06-09 2005-06-09 The Regents Of The University Of California Novel molecules for regulating cell death
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
US9492450B2 (en) * 2011-04-19 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of dynamin related protein 1 to promote cell death
US8759097B2 (en) * 2011-04-19 2014-06-24 University of Pittsburgh—of the Commonwealth System of Higher Eduction Inhibition of dynamin related protein 1 to promote cell death
JP2013142070A (ja) 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
CN105008515A (zh) 2012-12-28 2015-10-28 小利兰·斯坦福大学托管委员会 用于治疗线粒体疾病和用于使细胞分化成神经元的组合物和方法
US9289448B2 (en) 2013-03-15 2016-03-22 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating alzheimer's disease and other tauopathies
GB201522232D0 (en) 2015-12-16 2016-01-27 Liverpool School Tropical Medicine Combination product
CA3075649A1 (en) 2017-09-13 2019-03-21 Cerepeut, Inc. A novel small molecule compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150164896A1 (en) 2013-12-13 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment

Also Published As

Publication number Publication date
US11186550B2 (en) 2021-11-30
US11912669B2 (en) 2024-02-27
KR20200053560A (ko) 2020-05-18
US20220340534A1 (en) 2022-10-27
JP2020533399A (ja) 2020-11-19
IL273242B2 (en) 2023-08-01
AU2018331371A1 (en) 2020-04-02
AU2018331371C1 (en) 2024-05-09
CN111372921B (zh) 2023-12-01
US12404251B2 (en) 2025-09-02
IL273242A (en) 2020-04-30
IL273242B1 (en) 2023-04-01
JP7170341B2 (ja) 2022-11-14
EP3681874A1 (en) 2020-07-22
WO2019055528A1 (en) 2019-03-21
AU2018331371B2 (en) 2024-02-15
EP3681874B1 (en) 2022-04-06
EP3681874A4 (en) 2021-01-13
CN111372921A (zh) 2020-07-03
US20240246919A1 (en) 2024-07-25
US20200216400A1 (en) 2020-07-09
CA3075649A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
CN102239149B (zh) 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
US12404251B2 (en) Small molecule compound
JP2021527125A (ja) Ｓａｒｍ１阻害剤
DE102010035744A1 (de) Imidazolonylchinoline
JP6506291B2 (ja) 短縮型大腸腺腫性ポリポーシス（ａｐｃ）タンパク質を標的にする治療剤
CN109310666A (zh) 淫羊藿苷和淫羊藿素衍生物
JPH08502488A (ja) 前立腺癌および初期神経悪性疾患に対するベンゾキノイドアンサマイシンの殺腫瘍活性
DE102010025786A1 (de) Pyrazolochinoline
WO2014140072A1 (en) Etoposide and prodrugs thereof for use in targeting cancer stem cells
CA2922542A1 (en) Arylquinoline and analog compounds and use thereof to treat cancer
KR20170080447A (ko) 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 예방, 치료 및 전이 억제용 약학적 조성물
US12454514B2 (en) Quinazolinone compounds
CN100415219C (zh) 取代的二环[3.3.1]壬烷-2,4,9三酮作为活性药物成分
WO2021183760A1 (en) Methods of modulating t-cell activation using estrogen receptor beta (erβ) agonists
WO2017069913A1 (en) Chalcone compounds
WO2007062030A2 (en) Quinuclidinone derivatives as anticancer agents
KR101558050B1 (ko) 엔드리케리아 아노말라 추출물을 유효성분으로 포함하는 항암 조성물
EP4117660A1 (en) Methods of modulating t-cell activation using carboranes and carborane analogs
KR20100023681A (ko) 2,3-디하이드로-5-메톡시-2-페닐-4에이치-1-벤조피란-4-온의 항암제로서의 용도
HK40004069A (en) Icariin and icaritin derivatives
KR20090091119A (ko) 뇌암을 치료하거나 예방하기 위한 ｍｔ 키나아제 저해제의 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200410

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210910

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230501

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231201

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240229

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240229

End annual number: 3

Start annual number: 1

PG1601 Publication of registration